Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.
Latest from Alaric DeArment
The MMRF aims to incorporate a variety of new bispecific antibodies, cell therapies, checkpoint inhibitors and novel small molecules into the Horizon study.
Deal Snapshot: Gilead will pay $20m up front to the German biotech to develop an antibody-drug conjugate with a topoisomerase-1 payload meant to address durability and safety challenges.
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
The US FDA approved the TTR-stabilizing drug for ATTR-CM, with the drugmaker pricing it below that of Pfizer’s Vyndaqel/Vyndamax.
The San Diego-based firm had aggressively pursued Evotec, but the service provider based in Hamburg, Germany appeared uninterested in a buyout.